We anticipate that findings from this study will have an immediate impact to reduce the burden of unnecessary testing and its negative downstream consequences, provide insight on the optimal frequency and duration of cardiotoxicity surveillance in the evolving landscape of HER2-targeted treatment, prevent unnecessary delay or interruption of effective cancer care, and reduce inappropriate healthcare resource utilization that contributes to the rising cost of healthcare. The gene discussed is ERBB2; the disease is cancer.